Samsung Biologics Co.,Ltd.

KSE 207940.KS

Samsung Biologics Co.,Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: 75.61

Samsung Biologics Co.,Ltd. Price to Earnings Ratio (P/E) is 75.61 on January 14, 2025, a 21.63% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Samsung Biologics Co.,Ltd. 52-week high Price to Earnings Ratio (P/E) is 100,268.87 on December 20, 2024, which is 132,518.84% above the current Price to Earnings Ratio (P/E).
Samsung Biologics Co.,Ltd. 52-week low Price to Earnings Ratio (P/E) is 56.32 on June 26, 2024, which is -25.51% below the current Price to Earnings Ratio (P/E).
Samsung Biologics Co.,Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 479.77.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

KSE: 207940.KS

Samsung Biologics Co.,Ltd.

CEO	Mr. John Chongbo Rim
IPO Date	Nov. 11, 2016
Location	South Korea
Headquarters	300, Songdo Bio-daero
Employees	4,523
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Key trends

Past 5 years